These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11174074)

  • 1. Effect of KAD-1229, a nonsulfonylurea hypoglycemic agent, on plasma glucose and insulin in streptozotocin-induced diabetic dogs.
    Misawa K; Ichikawa K; Ojima K; Hamano S; Kitamura T; Komatsu H
    Pharmacology; 2001 Feb; 62(2):65-72. PubMed ID: 11174074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normalization of impaired glucose tolerance by the short-acting hypoglycemic agent calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate dihydrate (KAD-1229) in non-insulin-dependent diabetes mellitus rats.
    Ohnota H; Koizumi T; Kobayashi M; Momose Y; Sato F
    Can J Physiol Pharmacol; 1995 Jan; 73(1):1-6. PubMed ID: 7600439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rapid- and short-acting hypoglycemic agent KAD-1229 improves post-prandial hyperglycemia and diabetic complications in streptozotocin-induced non-insulin-dependent diabetes mellitus rats.
    Ohnota H; Kitamura T; Kinukawa M; Hamano S; Shibata N; Miyata H; Ujiie A
    Jpn J Pharmacol; 1996 Aug; 71(4):315-23. PubMed ID: 8886929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel rapid- and short-acting hypoglycemic agent, a calcium(2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide.
    Ohnota H; Koizumi T; Tsutsumi N; Kobayashi M; Inoue S; Sato F
    J Pharmacol Exp Ther; 1994 May; 269(2):489-95. PubMed ID: 8182516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a non-sulphonylurea hypoglycaemic agent, KAD-1229 on hormone secretion in the isolated perfused pancreas of the rat.
    Kinukawa M; Ohnota H; Ajisawa Y
    Br J Pharmacol; 1996 Apr; 117(8):1702-6. PubMed ID: 8732279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro insulinotropic action of a new non-sulfonylurea hypoglycemic agent, calcium (2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinyl-carbonyl) propionate dihydrate (KAD-1229), in rat pancreatic B-cells.
    Ohnota H; Kobayashi M; Koizumi T; Katsuno K; Sato F; Aizawa T
    Biochem Pharmacol; 1995 Jan; 49(2):165-71. PubMed ID: 7840793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide.
    Ikenoue T; Okazaki K; Fujitani S; Tsuchiya Y; Akiyoshi M; Maki T; Kondo N
    Biol Pharm Bull; 1997 Apr; 20(4):354-9. PubMed ID: 9145209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats.
    Ichikawa K; Yamato T; Ojima K; Tsuji A; Ishikawa K; Kusama H; Kojima M
    Clin Exp Pharmacol Physiol; 2002; 29(5-6):423-7. PubMed ID: 12010187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A rapid- and short-acting insulinotropic agent KAD-1229].
    Komatsu H; Ohnota H; Koizumi T; Satoh F
    Nihon Rinsho; 1997 Nov; 55 Suppl():171-9. PubMed ID: 9434463
    [No Abstract]   [Full Text] [Related]  

  • 10. Insulinotropic action of (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate. I. Secretory and cationic aspects.
    Malaisse WJ; Sato F
    Gen Pharmacol; 1995 Oct; 26(6):1313-8. PubMed ID: 7590125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulinotropic action of 2, 4-dinitroanilino-benzoic acid through the attenuation of pancreatic beta-cell lesions in diabetic rats.
    Jahan H; Choudhary MI; Manzoor M; Khan KM; Perveen S; Atta-Ur-Rahman
    Chem Biol Interact; 2017 Aug; 273():237-244. PubMed ID: 28625491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mitiglinide (KAD-1229)].
    Kusama H; Shibata N
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():559-65. PubMed ID: 12387051
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-diabetic and renoprotective effects of aliskiren in streptozotocin-induced diabetic nephropathy in female rats.
    Mahfoz AM; El-Latif HA; Ahmed LA; Hassanein NM; Shoka AA
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Dec; 389(12):1315-1324. PubMed ID: 27612855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoglycaemic effects of antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic and streptozotocin-induced severely diabetic rats.
    Tahara A; Matsuyama-Yokono A; Nakano R; Someya Y; Shibasaki M
    Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):560-8. PubMed ID: 18793271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals.
    Sato Y; Nishikawa M; Shinkai H; Sukegawa E
    Diabetes Res Clin Pract; 1991 Apr; 12(1):53-9. PubMed ID: 1906797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The in vivo interaction between gliclazide and glibenclamide and insulin on glucose disposal in the rat.
    Tanira MO; Furman BL
    Pharmacol Res; 1999 May; 39(5):349-56. PubMed ID: 10328992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihyperglycemic effects of M16209, a novel aldose reductase inhibitor, in normal and diabetic rats.
    Nakayama K; Murakami N; Ohta M; Kato K; Ida K; Mizota M; Miwa I; Okuda J
    Eur J Pharmacol; 1995 Mar; 276(1-2):77-83. PubMed ID: 7781698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Shiraki K; Hayakawa M; Shibasaki M
    Metabolism; 2009 Mar; 58(3):379-86. PubMed ID: 19217455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 55P0110, a Novel Synthetic Compound Developed from a Plant Derived Backbone Structure, Shows Promising Anti-Hyperglycaemic Activity in Mice.
    Brunmair B; Lehner Z; Stadlbauer K; Adorjan I; Frobel K; Scherer T; Luger A; Bauer L; Fürnsinn C
    PLoS One; 2015; 10(5):e0126847. PubMed ID: 25973898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of oxidative stress by a new low-molecular-weight antioxidant improves metabolic alterations in a nonobese mouse diabetes model.
    Novelli M; D'Aleo V; Lupi R; Paolini M; Soleti A; Marchetti P; Masiello P
    Pancreas; 2007 Nov; 35(4):e10-7. PubMed ID: 18090226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.